Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

LUN15-233

Randomized Phase II Trial of Docetaxel plus Nivolumab or Docetaxel alone in patients with advanced non-squamous NSCLC and previous clinical benefit on treatment with single agent Nivolumab.

Status: Open to Accrual

  • Condition: Non-squamous non-small cell lung cancer
  • Intervention:
    • Drug: Nivolumab
    • Drug: Docetaxel
  • Phase: Phase 2, randomized

For full description, see www.clinicaltrials.gov (study #NCT03041181).

Read a news release about this trial.

Funding for this study is provided by Bristol-Myers Squibb.

Project Manager: Donna Sullivan, dsullivan@hoosiercancer.org; (317) 634-5842, ext. 40.